Welcome to our dedicated page for Mind Medicine (MindMed) Common Shares news (Ticker: MNMD), a resource for investors and traders seeking the latest updates and insights on Mind Medicine (MindMed) Common Shares stock.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) is a biopharmaceutical company based in New York, specializing in the development of psychedelic-inspired medicines and therapies, known as psychoplastogens. The company's core mission is to address major mental health issues like addiction and mental illnesses through innovative treatments.
MindMed is at the forefront of a growing industry, assembling a comprehensive drug development pipeline focused on psychoplastogens. These substances have shown great potential in treating brain health disorders, and MindMed is committed to rigorous scientific research to unlock their therapeutic benefits.
One of the company's most significant recent achievements is the positive data from its Phase 2b clinical trial of MM120 (lysergide d-tartrate) for treating generalized anxiety disorder (GAD). The trial results indicated a substantial improvement in participants, with 48% achieving remission and 65% showing clinically meaningful improvement four weeks after a single dose. This breakthrough has led the U.S. Food and Drug Administration (FDA) to designate MM120 for GAD as a breakthrough therapy, reflecting the significant unmet medical need in this area.
MindMed collaborates extensively with other organizations and clinical research sites, such as Numinus Wellness Inc., to advance its clinical trials. With a research network spanning 20 sites and involving 198 participants, MindMed ensures robust and reliable clinical data.
The company's approach is unique, focusing purely on the effects of its treatments without the interference of other medications or therapies. This has allowed for a clear understanding of the efficacy and potential of their psychedelic-inspired medicines.
Financially, MindMed is well-positioned to continue its pioneering work. The company leverages its partnerships and collaborations to support its research and development efforts, aiming to bring these novel treatments to market.
With a vision to transform mental health care, MindMed is leading the way in integrating psychedelic-assisted therapies into mainstream clinical practice. The company’s ongoing projects and positive clinical outcomes signal a promising future in addressing some of the most prevalent mental health disorders.
MindMed (NASDAQ: MNMD) has appointed Gregg A. Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer. Dr. Pratt will oversee regulatory and quality functions, as well as product registration strategies as the company prepares to launch three Phase 3 studies of MM120 orally disintegrating tablet for generalized anxiety disorder (GAD) and major depressive disorder (MDD). Dr. Pratt brings over 30 years of experience in drug development and previously led the regulatory approval of COBENFY™ at Karuna Therapeutics. As part of his appointment, Dr. Pratt received an inducement award of options to purchase 350,000 common shares, vesting over four years.
MindMed (NASDAQ: MNMD), a clinical-stage biopharmaceutical company focused on brain health disorders, has announced its participation in two upcoming investor conferences. The company will attend the Jefferies London Healthcare Conference for one-on-one meetings on November 20-21, 2024, in London, UK. Additionally, MindMed will participate in the 7th Annual Evercore HealthCONx Conference on December 5, 2024, in Coral Gables, FL, featuring a fireside chat at 11:15 PM ET. Audio webcasts and replays will be available on MindMed's Investor Relations website for 90 days after each event.
MindMed (NASDAQ: MNMD) reported Q3 2024 financial results and provided updates on its clinical programs. The company is preparing to launch three Phase 3 studies, including the Voyage study for GAD in Q4 2024, with topline data expected in H1 2026. Cash position stands at $295.3 million, expected to fund operations into 2027. Q3 2024 saw R&D expenses of $17.2 million and net loss of $13.7 million. The company's MM120 ODT program is advancing with additional Phase 3 studies Panorama (GAD) and Emerge (MDD) planned for H1 2025, targeting conditions affecting approximately 51 million U.S. adults.
MindMed (NASDAQ: MNMD), a clinical-stage biopharmaceutical company focused on brain health disorders, has scheduled a conference call and webcast for Thursday, November 7, 2024, at 4:30 p.m. ET. The event will cover the company's third quarter 2024 financial results and provide a corporate update. The webcast will be accessible through a registration link, with a replay available on the company's investor relations website for at least 30 days. Participants are encouraged to join 15 minutes before the start time.
MindMed (NASDAQ: MNMD), a clinical-stage biopharmaceutical company focusing on brain health disorders, has announced the issuance of inducement grants to three newly hired non-executive employees. The grants consist of options to purchase a total of 70,000 common shares of the Company, effective September 9, 2024. These options have an exercise price equal to the closing price of MindMed's common shares on September 6, 2024, and will vest over a four-year period. The vesting schedule includes 25% vesting on October 1, 2025, with the remaining 75% vesting in substantially equal monthly increments over the following three years, subject to continued employment.
The options were granted outside MindMed's equity incentive plans as a material inducement to employment and were approved by the Company's Compensation Committee on September 6, 2024, in compliance with NASDAQ Stock Market rules.
MindMed (NASDAQ: MNMD), a clinical-stage biopharmaceutical company focused on brain health disorders, has announced its participation in three major investor conferences in September 2024. The company will be involved in:
1. A panel discussion on psychedelics in psychiatry at the H.C. Wainwright Global Investment Conference on September 10.
2. A fireside chat at Baird's Global Healthcare Conference on September 11.
3. Another fireside chat at the Cantor Global Healthcare Conference on September 17.
All events will take place in New York, NY. Audio webcasts and replays of available presentations will be accessible on MindMed's Investor Relations website for up to 90 days after each event, providing investors with extended access to the company's insights and updates.
MindMed (NASDAQ: MNMD) reported Q2 2024 financial results and provided business updates. Key highlights include:
1. Completed End-of-Phase 2 meeting with FDA for MM120 ODT in GAD
2. Phase 3 clinical program for MM120 ODT in GAD to start in H2 2024
3. Expanding pipeline with MM120 ODT for MDD, registrational study planned for H1 2025
4. New patent extends MM120 ODT IP protection through 2041
5. $243.1M cash balance as of June 30, 2024
6. Recently closed $75M gross proceeds offering
7. Cash runway extended into 2027
Financial results: R&D expenses $14.7M, G&A expenses $9.8M, net loss $5.9M for Q2 2024. The company expects its first Phase 3 clinical readout for MM120 ODT in GAD in H1 2026.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), a clinical stage biopharmaceutical company focusing on brain health disorders, has announced the pricing of a public offering. The offering includes 9,285,511 common shares at $7.00 per share and pre-funded warrants for 1,428,775 common shares at $6.999 per warrant. The gross proceeds are expected to be approximately $75 million. MindMed plans to use the funds for research and development of product candidates, working capital, and general corporate purposes. The offering, managed by Leerink Partners and Evercore ISI as joint bookrunners, is expected to close around August 12, 2024. The securities are being offered through an effective shelf registration statement on Form S-3.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), a clinical stage biopharmaceutical company focused on brain health disorders, has announced a proposed public offering of common shares and pre-funded warrants. The offering, managed by Leerink Partners and Evercore ISI as joint bookrunners, aims to fund research and development of product candidates, working capital, and general corporate purposes. RBC Capital Markets and Oppenheimer & Co. are acting as lead managers. The securities will be offered through an effective shelf registration statement on Form S-3. The offering's completion and terms are subject to market conditions, with no assurance of its finalization. No distribution will occur in Canada or to Canadian residents.
MindMed, a clinical-stage biopharmaceutical company focused on brain health disorders, has announced its participation in Canaccord Genuity's 44th Annual Growth Conference. The company's management team will engage in a fireside chat on Tuesday, August 13, 2024, at 1:30 PM ET in Boston, MA.
This presentation offers investors and interested parties an opportunity to gain insights into MindMed's progress and future plans. The event will be accessible via audio webcast, with replays available on MindMed's Investor Relations website for up to 90 days after the conference. This participation underscores MindMed's commitment to engaging with the investment community and showcasing its developments in the field of brain health therapeutics.
FAQ
What is the current stock price of Mind Medicine (MindMed) Common Shares (MNMD)?
What is the market cap of Mind Medicine (MindMed) Common Shares (MNMD)?
What does Mind Medicine (MindMed) Inc. do?
What is MM120?
What were the results of the Phase 2b clinical trial for MM120?
What is the FDA's designation for MM120?
Who are MindMed's partners in clinical research?
What are psychoplastogens?
Where is MindMed based?
What mental health issues does MindMed focus on?
How does MindMed's approach differ in clinical trials?
What is the significance of MindMed's recent achievements?
